Zodasiran

Phase 3RNA therapy

Zodasiran is one of 27 small molecule programs targeting Homozygous Familial Hypercholesterolemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Homozygous Familial HypercholesterolemiaActive, not recruiting

Homozygous Familial HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Homozygous Familial Hypercholesterolemia

#DrugCompanyPhaseTrials

EVKEEZA

Regeneron

Phase 3

4 2

Leqvio

Novartis

Phase 3

3 3

Crestor

AstraZeneca

Phase 3

3 4

Praluent

Regeneron

Phase 3

2 5

Lescol

Novartis

Phase 3

1 6

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 7

Zocor

OOrganon and Co

Phase 3

2 8

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 9

Tricor

JJagotec

Phase 3

1 10

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Homozygous Familial Hypercholesterolemia

NCT07037771

Q2 2029

Phase 3Not yet recruiting

Homozygous Familial Hypercholesterolemia

NCT07473843

Clinical

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia2 trials

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT07037771·60 enrolled

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Not yet recruiting· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 3·NCT07473843·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Zodasiran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zodasiran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zodasiran. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arrowhead Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 3[1]
Company: Arrowhead Pharmaceuticals

Zodasiran

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2029

Trials by Indication[1]

Homozygous Familial Hypercholesterolemia2 trials

References

Drug Info

Quick Facts

Related News